

ISoP General Assembly

26 October 2025

InterContinental Cairo Semiramis Hotel (Cleopatra Ballroom) Corniche El Nil, Garden City, Cairo, Egypt.
14:00 to 16:00 UTC+3

Present: Angela Caro-Rojas (Society President), Brian Edwards (Vice-President), Mónica Tarapués (Secretary General), and Omar Aimer (Treasurer).

Advisory Board members: Mayada Alkhakany, Ghita Benabdallah, Maribel Salas, Francesco Salvo and Manal Younus.

Apologies: Li Zhang.

Approximately 300 members of the Society and 30 Society members connected online.

Chairs: Society President Angela Caro-Rojas and Secretary General Mónica Tarapués.

Agenda

- 1. Welcome, introductions, housekeeping**
- 2. Approval of Agenda**
- 3. Approval of Minutes GA 2024**
- 4. Overview of the strategic plan**

Introduction

- 4.1. Goal 1 - Long-term financial and organisational sustainability and stability of ISoP
 - 4.1.1. By-laws Update for adoption and ISoP documents
 - 4.1.2. Financial Report
 - 4.1.3. Membership Report
- 4.2. Goal 2. Create and build a community for optimising the safer use of medicine
 - 4.2.1. Communication Team Report
 - 4.2.2. Overview of ISoP activities 2025 and partnership
- 4.3. Goal 3- Maintain and enhance scientific knowledge and competencies in the global pharmacovigilance community
 - 4.3.1. Report from Chapters
 - 4.3.2. Report on SIGs

5. Fellowship and Honorary Awards 2025

6. Advisory Board Elections

6.1. Advisory Board election results

6.2. Remarks from new ISoP President

7. Questions and Answers (time permitted)

1. Welcome, introductions, housekeeping

ISoP President Angela Caro-Rojas opened the General Assembly by warmly welcoming members from around the world. Held as a hybrid event and streamed live from Cairo during the 24th ISoP Annual Meeting, the session was open online to all ISoP members.

Angela Caro-Rojas reflected on ISoP's origins, its evolution into an international society, and its 25th anniversary theme video — "[Honouring the Past, Embracing the Present, and Looking to the Future.](#)"

2. Approval of Agenda

ISoP Secretary General Mónica Tarapués requested approval of the agenda, which was accepted by the General Assembly without amendments.

3. Approval of Minutes GA 2024

Secretary General Mónica Tarapués requested approval of the 2024 General Assembly minutes, which were accepted by the General Assembly (the General Assembly minutes have been posted on the ISoP website: (<https://isoponline.org/about-isop/general-assembly-reports/>).

4. Overview of the ISoP Strategic Plan

Short Introduction

President Angela Caro-Rojas gave an overview of ISoP, founded in 1992 as ESOP (European Society of Pharmacovigilance) and became ISoP (International Society of Pharmacovigilance) in 2000, a non-profit, independent organization, funded by membership fees. In 2025 ISoP is recognized as the leading global champion for education and research in pharmacovigilance and the safe use of medical products and devices.

After introducing the Executive Committee and Advisory Board, Scientific Board and the communities (Honorary/Fellow members and Students group), Angela Caro-Rojas outlined the following three main goals. Angela Caro-Rojas presented the progress made under the 2022–2025 ISoP Strategic Plan, structured around three goals.

4.1. Goal 1 - Long-term financial and organisational sustainability and stability of ISoP

Key achievements included strengthening financial governance, defining clear budgetary rules, introducing sponsorship frameworks, and doubling membership from around 700 to 1,455 members. The ISoP Secretariat improved operational efficiency through updated guidelines, and the creation of new governance documents (e.g., partnership guidelines, student travel grants, speaker pool, and Scientific Board procedures).

4.1.1. By-laws Update for adoption and ISoP documents

A summary of the proposed changes to the ISoP By-laws was shared with all members on 30 July 2025 in preparation for formal adoption.

The first set of revisions focuses on Article 3 – Membership, starting with Section (vii), which has been updated to align with the new Chapters Guidelines. Under the revised section, ISoP members within a specific geographical region may establish a chapter to support the organization of meetings, training courses, and other activities that advance ISoP's mission. Typically, a minimum of fifty members is required to form a chapter, unless the Executive Committee agrees otherwise.

Previous By-laws Stated

vii) ISoP members in one country or geographical region may form a chapter to facilitate the organisation of meetings, training courses, or other activities related to the missions of ISoP. Normally at least ten members are needed to constitute a national chapter unless agreed with the Executive Committee.

Comment from the Assembly: Jean-Christophe Delumeau (Canada) raised a question on how this change would affect existing smaller chapters. The response clarified that current chapters with fewer than 50 members would remain but would be encouraged to merge or grow through increased activities and engagement.

A second update under Article 3, Section (viii), concerned the establishment of Special Interest Groups (SIGs). A Special Interest Group (SIG) can be initially created by at least five ISoP members to discuss and work on a specific and relevant topic which is within the scope and aims of ISoP.

Previous By-laws Stated

viii) A Special Interest Group (SIG) can be created by at least five ISoP members to discuss and work on a specific and relevant item which is within the scope and aims of ISoP.

Comment from the Assembly: Jean-Christophe Delumeau asked what would happen if a SIG failed to expand; the response confirmed that while initial formation requires five members, SIGs will be encouraged to increase participation and continue operating under existing guidelines.

This section also introduced a new category—Communities—which formally recognises groups united by shared interests or backgrounds (e.g., students, fellows, industry professionals). The text defines a community as a group of ISoP members approved by the Executive Committee, collaborating to advance pharmacovigilance and the Society’s objectives.

Comments from the Assembly included concerns from Linda Härmark (UK) about distinguishing chapters, SIGs, and communities; further suggestions from Marie Lindquist (Sweden) and Priya Bahri proposed rewording to ensure the definition clearly reflected stakeholder groups or shared professional backgrounds.

The Assembly agreed to incorporate minor revisions before approval.

Proposed changes were also presented under Article 4- Membership fee

ii) - Update Article – As a compensation for the considerable input of voluntary time expected of all elected members of the Advisory Board, their membership fees will be waived during the length of their active service on the Advisory Board.

Previous By-laws Stated

ii) As a compensation for the considerable input of voluntary time expected of elected members of the EC, their membership fees will be waived during the length of their active service on the EC

Another related change to Article 5 - Admission to membership and data protection

5.1 – Updated Article to New applications for membership will be reviewed by the Secretary and the Executive Secretary of ISoP Secretariat., reflecting the Society's growth to more than 1,400 members.

Previous By-laws Stated

5.1 New applications for membership will be reviewed by the Secretary or the President before final approval of the application.

Comment from the Assembly: Dennis Van Liew requested clarification on whether applications would be reviewed by both parties or either; it was confirmed to be the latter. François Audibert also commented on this topic during the online Zoom session.

The revision of Article 9 - The Advisory Board of ISoP

9.4 – Updated section – All members of the Board will have a specific role, as follows.

Four members (President, Vice-President, Secretary, Treasurer) will form the Executive Committee.

- One member will be responsible for coordination of ISoP Chapters.
- One member will be responsible for coordination of ISoP Special Interest Groups.
- The remaining members will be assigned any other responsibility as directed by the Executive Committee. It is recommended to have an Academic coordinator, a Strategy and Innovation leader, a Communication leader, and a Community coordinator.

Comment from the Assembly: Hadir Rostom (Egypt) asked whether additional roles could be added; it was confirmed the structure would remain adaptable.

Under Article 11 - Executive Committee

Addition of a new Article (11.3):

11.3 The Executive Committee has the authority to grant special recognition to outstanding ISoP members who have carried out voluntary work within the organization.

Annex 3 – Scientific Board (SB) Mission and Objectives was updated in line with the new SB Terms of Reference, available on the ISoP website. The mission is to support ISoP's scientific and educational activities and provide expert advice globally. The SB will meet to address matters raised internally or by the Executive Committee or Advisory Board. Activities may include contributing to publications, offering scientific authority to ISoP projects, and participating in special initiatives.

Additional approved amendments included an adjustment to Advisory Board meeting frequency, recommending virtual meetings every two months; revisions to the Fellows section, formally integrating the Fellows Group into the Fellowship Subcommittee; and a change assigning responsibility for approving Fellowship criteria to the Advisory Board rather than the General Assembly. The timeline for Fellowship applications will remain flexible between six and two months.

The updated section on the Responsibilities of members of the Advisory Board

Updated text

Meetings

- i) Members of the Board are expected to attend in person at least one face-to-face Board meeting per year during the annual meeting. It is also recommended to have Board meetings every two months (virtual meetings).

Previous By-laws Stated

Meetings

- i) Members of the Board are expected to attend in person at least one face-to-face Board meeting per year during the annual meeting

Updates to the Appointment of Fellows of the Society

- i) Within the Advisory Board, a Fellows Nominations Sub-Committee (FNSC) is established, comprised of the ISoP Secretary (chair) and two other members of the EC/Advisory Board or Fellowship group. The ISoP Secretary invites other members of the EC/AB or Fellowship group to volunteer for these positions by email. If there are more than two members wishing to be on this sub-committee, the Secretary will discuss with the President and their decision will be final.
- ii) The FNSC considers applications for ISoP Fellowship submitted to them by members. Assessment is according to the criteria approved by the Advisory Board.

Previous By-laws Stated

- ii) The FNSC considers applications for ISoP Fellowship submitted to them by members. Assessment is according to the criteria approved by the General Assembly.

- iv) There is an annual timetable for this process, to allow ideally between six and two months to apply, from the closing date for submissions, through to announcement of new ISoP Fellows at the General Assembly.

Toward the conclusion of the session, Luis Velez (Switzerland) proposed an amendment to shorten the ISoP President's term from three years to encourage leadership renewal. The President noted this would be addressed later under "questions and answers."

All proposed amendments to the By-laws were approved, subject to minor clarifications and wording updates to reflect ISoP's continued growth and evolving structure.

4.1.2. Financial Report

Treasurer Omar Aimer presented the Financial Report for the 2024–2025 financial year (October 1, 2024 – September 30, 2025). Omar Aimer reported a 10% increase in income compared with the previous year, equivalent to approximately €14,000, mainly due to expanded training activities, regional symposia, and events such as the Intelligent Automation Seminar in Boston, the Mid-Year Symposium in Uppsala, and the Montreal Annual Meeting. Expenses also increased by 6.1%, largely driven by higher administrative and website maintenance costs, and inflation. He explained that the Drug Safety journal access—included as part of ISO-P membership—remains a significant cost, with €40 per member for high-income countries and €25 for low- and middle-income countries.

The treasurer detailed additional operational expenses, including investment in new laptops for the Secretariat, website upgrades, and marketing to enhance ISO-P's visibility and digital engagement. He emphasized that ISO-P's main income continues to come from membership fees, which ensure the Society's financial independence. He concluded that ISO-P had achieved financial stability, closing the fiscal year with a near break-even result (a minimal loss of 0.5%), and is leaving the next Advisory Board a healthy financial position and a solid foundation for continued growth.

	2022	2023	2024	2025
				Last cycle before COVID impact
EUR	2021.10.01 2022.09.30	2022.10.01 2023.09.30	2023.10.01 2024.09.30	2024.10.01 2025.09.30
Current Asset	269'256	278.446	259'121	+259'782
Liabilities	-11'056	-7'849	-19'325	-7'259
Net Assets	262'457	242.419	236'675	236'062
Variation vs previous period	-10'221 -3.8%	-20'038 -7.6%	-4'789 -1.98%	-613 -0.26%

The accounts were accepted by the General Assembly.

Angela Caro-Rojas thanked Omar Aimer for his detailed report and for his contributions toward maintaining ISO-P's financial stability.

4.1.3. Membership Report

Secretary General Mónica Tarapués presented the Membership Report, noting a significant 80% increase in ISO-P membership from 2022, reaching a record 1,455 members—the first time the Society has surpassed 1,000. Members now represent a wide range of stakeholder groups, including industry, academia, students, regulatory authorities, and public health organizations, with an increasingly balanced distribution between members from high-income and low- and middle-income countries, reflecting ISO-P's growing diversity. Membership growth was attributed to enhanced engagement through chapter activities, including regional meetings in Mérida, Kampala, and events such as the Boston IA Seminar and the Annual Meeting in Montreal.

4.2. Goal 2. Create and build a community for optimising the safer use of medicine

To reach Goal 2, the following activities were presented at the General Assembly:

4.2.1. Communication Team Report

Angela Caro-Rojas discussed the progress made toward Goal 2 of ISoP's Strategic Plan: building a stronger community for optimizing the safe use of medicines. A membership survey helped identify members' priorities, leading to the introduction of monthly educational and networking events, both virtual and in-person, which increased visibility, participation, and engagement. ISoP's communication strategy was further strengthened through the use of infographics, social media updates, and real-time event coverage. The Society now has nearly 20,000 social media followers across its platforms, with over 5,000 YouTube video views and 80,000 post impressions.

Angela Caro-Rojas highlighted the ongoing effort to convert social media followers into active members and to improve access to ISoP resources through the website. To address limited awareness of online materials, the Society launched tutorial videos—including guidance on how to navigate the ISoP website and participate in elections—which are now available on ISoP's YouTube channel. Mónica Tarapués added that these initiatives were made possible through ISoP's growing communications team, supported by a dedicated community manager.

4.2.2. Overview of ISoP activities 2025 and partnership

ISoP maintained an active programme throughout the year, hosting one to three events per month across virtual and in-person formats. Webinars focused on collaboration between Chapters, SIGs, and partner institutions, with thematic series on antimicrobial resistance and substandard and falsified medical products, drawing over 750 participants.

ISoP strengthened its global partnerships through formal MoUs with organisations.

- International Ergonomic Association (IEA)
- Council for International Organizations of Medical Sciences (CIOMS)
- World Health Organization (WHO) & Coalition of Interested Parties/CIP Network
- Institute for Safe Medication Practices (ISMP)
- Uppsala Monitoring Centre (UMC)
- European programme in Pharmacovigilance and Pharmacoepidemiology (Eu2P)
- European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) Steering Group
- Rabat Collaborating Center (RCC)
- International Medication Safety Network (IMSN)

- ARCS Australia Limited

The 5th ISoP Patient Safety Day was a major highlight, featuring seven sessions, 117 speakers, and strong regional participation, achieving over 1,800 online views. The President thanked the regional coordinators for their dedication to this initiative and reaffirmed ISoP's commitment to strengthening global collaboration and scientific excellence in pharmacovigilance.

4.3. Goal 3- Maintain and enhance scientific knowledge and competencies in the global pharmacovigilance community

4.3.1. Report from Chapters

Francesco Salvo presented the Chapters Report, noting that ISoP currently has 13 active chapters coordinated by 12 regional leads worldwide, ranging from large regional chapters (Europe, North America, Latin America, and Africa) to smaller chapters (less than 50 members) (UK & Ireland, Middle East, Western Pacific, Switzerland, Italy, Egypt, South Asia, China, and Indonesia). In line with the new By-laws, efforts will focus on strengthening the activity and visibility of smaller chapters.

Key highlights for 2025 included successful events such as the 7th Latin American Chapter Symposium in Mérida, a joint meeting with DIA India, and the Western Pacific Chapter's webinar titled "From Signals to Clinical Evidence." Initiatives are also underway to revitalize the China Chapter and encourage broader regional engagement.

4.3.2. Report on SIGs

Date of creation	Special Interest Group (SIG)	Responsible
2011	Women's medicines	Mira Harrison-Woolrych (New Zealand)
2014	Risk communication	Priya Bahri (Netherlands)
2015	Risk Minimization Methods	Jean-Christophe Delumeau (Canada)
2017	Herbal and Traditional medicines	Souad Skalli (Morocco)
2017	PV Professional Qualification Framework	Jan Petracek (Czech Republic)
2017	Medication Errors	Brian Edwards (UK)/Angela Caro-Rojas (Colombia)
2019	Vaccines	Rebecca Chandler (Sweden)
2020	Pharmacogenomics	Qun-Ying Yue (Sweden)
2021	Medical Devices	Ladi Owolabi (USA)
2021	Patient Engagement	Mayada Alkhakany (Iraq) /Manal Younus (Iraq)
2022	EcoPharmacovigilance	Jayesh Pandit (Kenya)
2022	Drug Safety in Older Patients	Giovanni Furlan (Italy)
2023	Real World Evidence and Big Data	Gianluca Trifirò (Italy)
2024	PV in the community	Rebecca Noss (USA)
2024	Artificial Intelligence in PV	Mohammed Fouda (Saudi Arabia)

2025	★ Advanced Therapy Medicinal Products & RP (new)	Jim Carlson (UK)
------	--	------------------

Maribel Salas, the ISoP SIGs co-ordinator, presented an overview of the Special Interest Groups (SIGs) explaining their purpose and structure. Unlike Chapters, which are organized geographically, SIGs are thematic and focus on specific scientific topics. ISoP began with 12 SIGs in 2022 and has since expanded to 16, reflecting the evolving scope of pharmacovigilance. Maribel Salas welcomed the creation of the new SIG on Advanced Therapy Medicinal Products & RP.

SIG activities over the past year included webinars, collaborative research projects, publications, educational sessions, and partnerships with external organizations.

Members interested in joining SIGs were encouraged to contact the ISoP Secretariat for guidance (isoponline.org)

Maribel Salas also reported on the establishment of formal Communities within ISoP, now distinct from SIGs. The Student Community—previously managed through SIGs—has been formalized, and a new Industry Community is being developed to engage professionals across sectors, including academia, regulatory authorities, and industry. The new community structure aims to foster collaboration among members with shared professional backgrounds and interests.

4.3.3 Report on Communities: Students, Scientific Board, Fellows

Student Community Report

Manal Younus presented the Student Community Report, thanking the advisory and coordinating committees for their strong collaboration. The ISoP Student Group, officially approved in 2023, now includes students from 37 countries. It operates through two committees: an Advisory Committee (non-students providing guidance and mentorship) and a Coordinating Committee (student representatives leading activities). Manal Younus announced the approval of the new ISoP Student Travel Grant, endorsed by the Advisory Board and Executive Committee, to support students in attending ISoP meetings and presenting their research. The group also collaborates with international student organizations such as IFMSA and IPSF and is working jointly with the Fellows Community to launch a mentorship programme connecting students with senior pharmacovigilance professionals for career and research development.

Scientific Board Report

Brian Edwards then delivered the Scientific Board Report on behalf of Veronique Kugener as Chair and Marco Tuccori as Co-chair, highlighting its establishment in 2022 to support ISoP's scientific and educational initiatives. The Board includes 12 core members and provides expert consultation to the Advisory Board and Executive Committee. Major accomplishments include the update of the WHO–

ISoP Pharmacovigilance Curriculum, led by Prof. Jürgen Beckmann, with contributions from 82 experts worldwide.

Fellows

Brian Edwards also shared an update from the ISoP Fellows, represented on behalf of Ken Hartigan-Go and Santiago Schiaffino, outlining plans to formalize a mentorship policy in collaboration with the Student Group and to expand Fellows' roles in career development, research promotion, and professional networking.

5. Fellowship and Honorary Awards 2025

ISoP Fellows have made substantial contributions to the discipline of pharmacovigilance through their work (including publications or similar outputs) and have also shown services to the Society, for example, by involvement in ISoP meetings, and/or by leadership of ISoP Chapters and Special Interest Groups (SIG's).

Mónica Tarapués, Secretary General and Chair of the Fellowship Nominations Sub-Committee (FNSC), and Angela Caro-Rojas, ISoP President announced the 2025 cohort of ISoP Fellows.

They are (in alphabetic order):

- Felix Arellano,
- Jürgen Beckmann,
- Linda Härmark,
- Hadir Rostom, and
- Francesco Salvo

The new fellows received their certificates from President Angela Caro-Rojas.

Honorary Membership Award 2025

President Angela Caro-Rojas, on behalf of the Executive Committee, proposed to the General Assembly the nomination of Dr. Jürgen Beckmann as ISoP Honorary Member.

Dr. Beckmann has been a dedicated member since ISoP's foundation in 2000, contributing over 25 years of service to the Society and its predecessor, ESOP. A former Head of Pharmacovigilance at BfArM, he has also served on the EU Committee for Proprietary Medicinal Products (CPMP/CHMP), the WHO Collaborating Centre for International Drug Monitoring, the WHO Advisory Committee on the Safety of Medicinal Products, and the German Medical Association's Drug Committee.

He previously held the position of ISoP Vice President (2000–2003), led the development of the WHO–ISoP Pharmacovigilance Curriculum, and continues to contribute to its ongoing update.

In addition, certificates of appreciation were awarded to Rabih Dabliz (Communication Team) and Emiliano Capello (Scientific Board Secretariat).

Looking forward: plans for the year ahead (2025-2026)

9th ISoP IA Seminar 2025	4-5 December 2025	Boston, Cambridge, USA	“From Innovation to Impact: Building Trustworthy AI in Pharmacovigilance”
1st ISoP European AI Seminar Basel 2026	16–17 February 2026	Basel, Switzerland	Artificial Intelligence-Powered Pharmacovigilance: Humans in the Loop
ISoP Mid-Year Symposium 2026	9-10 June 2026	Hatfield, UK	Collaboration in Pharmacovigilance in an evolving information environment.
ISoP 25th Global Meeting	22–25 September 2026	San José, Costa Rica	“Ecosystems of trust: Pharmacovigilance for a healthier world”

Final Acknowledgments

President Angela Caro-Rojas expressed appreciation to the Executive Committee and Advisory Board members for their dedication and support. Special thanks were given to the Egypt Chapter and the ISoP 2025 Local Organizing Committee for their efforts. Additional recognition was provided to Brian Edwards and Hadir Rostom for their significant contributions. President Caro-Rojas also thanked Sophie Spence, Antoinette Ivins (ISoP Administration), Gabriela Durán (ISoP Comms & Design) and all involved in ISoP for their support and contribution.

6. Advisory Board Elections

6.1. Advisory Board election results

President Angela Caro-Rojas (2022-2025 period) presented the results of the election for the Advisory Board, including the new President (2025-2028 period).

The election process was conducted by Dr. Mira Harrison-Woolrych (Chair of the Nominations Committee, Past President) and Angela Caro-Rojas.

The results of the new Advisory Board were announced as follows including the number of votes (not presented in the General Assembly): Among the 33 pre-selected candidates, the following 10 received the highest number of votes and were considered elected as Advisory Board Members of ISoP.

	Name, Given name	Number of votes	
1	Aimer, Omar	285	elected
2	Salvo, Francesco	206	elected
3	Salas, Maribel	196	elected
4	Ogar, Comfort	168	elected
5	Rostom, Hadir	158	elected
6	Hammad, Tarek	154	elected
7	Edwards, Brian	144	elected
8	Ilic, Katarina	137	elected
9	Villalobos, Felipe	132	elected
10	Crisafulli, Salvatore	130	elected

The following persons are no longer members of the Executive Committee and Advisory Board: Mayada Alkhakany, Ghita Benabdallah, Mónica Tarapués, Manal Younus, and Li Zhang.

Angela Caro-Rojas is part of the Advisory Board in her capacity as Immediate Past President.

Angela Caro-Rojas thanked all outgoing Executive Committee and Advisory Board members by distributing a certificate to each of them.

She warmly congratulated the new ISoP President Omar Aimer and wished successful work to the new Executive Committee and Board. The new President, Omar Aimer, also thanked Angela Caro-Rojas for her leadership as outgoing President and the previous Executive Committee members who have paved the way for ISoP's future.

The new Advisory Board elections elected Dr Omar Aimer as President, who then selected the following Board members as Executive Committee members:

ISoP Executive Committee

- President - Omar Aimer
- Vice President - Francesco Salvo
- Secretary General - Felipe Villalobos
- Treasurer - Comfort Ogar

ISoP Advisory Board

- Communication & Students Coordinator - Salvatore Crisafulli
- Communities & Mentorship Coordinator - Brian Edwards
- Strategy & Innovation Coordinator - Tarek Hammad
- Special Interest Groups Coordinator - Katarina Ilic
- Membership Coordinator - Hadir Rostom
- Academic Coordinator - Maribel Salas

6.2. Remarks from new ISoP President – 2025-2028

As he begins his presidency, President Omar Aimer emphasizes two main pillars for the Society over the next three years: empowering our members by fostering engagement, recognizing expertise, supporting growth, and preparing the next generation of leaders; and leveraging science by advancing pharmacovigilance as a dynamic scientific discipline, ensuring ISoP remains a global reference in patient safety, innovation, and credibility.

7. Questions and Answers (Q&A)

The assembly concluded with a brief Questions and Answers session.

Luis Velez (Switzerland) proposed reducing the presidency and board terms from three years to shorter periods, suggesting this could bring fresh ideas. Angela Caro-Rojas clarified that the current elected board serves a three-year term, and any change would require a formal proposal and amendment of the bylaws at a future assembly. Mónica Tarapués expressed concern over the suggestion to shorten Executive Committee terms, emphasizing that continuity is essential for progress and that three years is already short. Jean-Christophe Delumeau (Canada) also mentioned that it is not wise to have terms shorter than three years.

Priya Bahri (Netherlands) raised the need for an improved web platform for members to manage community registration and distribution lists efficiently. The response confirmed that the Society is working on streamlining processes, automating administrative tasks where possible, and engaging students to support ISoP activities, aiming to reduce workload.

George Sabblah (Ghana) reminded the team to play a video for the upcoming African chapter in Namibia (May 2026).


Liana Kasyan (Armenia) highlighted the risk of segregating regions while expanding chapters, particularly noting the small size of the Eurasian chapter, and suggested strategies to encourage regional inclusivity. Francesco Salvo responded that this would be an Executive Committee strategic matter, with careful consideration during upcoming elections and chapter discussions.

Omar Aimer recognized Jean-Christophe Delumeau for his encouragement and support, and the assembly formally concluded with thanks to the outgoing Advisory Board (2022–2025).

The General Assembly concluded with sincere appreciation to all members and contributors for their dedication to advancing pharmacovigilance and the safer use of medicines worldwide. Participants were warmly invited to attend the next **ISoP 25th Global Meeting**, to be held in **San José, Costa Rica**, from 22-25 September 2026.

The meeting closed at 16:30 UTC+3

Date:



Angela Caro-Rojas
President



Mónica Tarapués MD. PhD
Secretary General